LON:CRTX CRISM Therapeutics (CRTX) Share Price, News & Analysis GBX 9 -0.50 (-5.26%) (As of 05:19 AM ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitors About CRISM Therapeutics Stock (LON:CRTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CRISM Therapeutics alerts:Sign Up Key Stats Today's Range 9▼ 9.7350-Day Range 8.16▼ 11.9052-Week Range 5▼ 30.90Volume9,842 shsAverage Volume100,242 shsMarket Capitalization£2.94 millionP/E Ratio1.09Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewCRISM Therapeutics Corporation focuses on drug delivery technology to improve the clinical performance of cancer drugs as treatments for solid tumors. Its lead product, ChemoSeed that can be implanted directly into a tumor or the resection margin following the removal of a tumor, ensuring effective therapeutic concentrations of chemotherapy drugs directly reach the tumor tissue. Its ChemoSeed used for treatment of gliomas, a brain tumor. The company was founded in 2016 and is based in Road Town, the British Virgin Islands.Read More… Central Bank Abandons USD (Ad)You know what doesn't care about elections? Gold. If you want to protect your savings & retirement from our exploding national debt, VOTE FOR GOLD! Get Your FREE Gold Investor Kit NOW! Receive CRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CRISM Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CRTX Stock News HeadlinesNo headlines for this company have been tracked by MarketBeat.com CRTX Stock Analysis - Frequently Asked Questions How have CRTX shares performed this year? CRISM Therapeutics' stock was trading at GBX 11.90 at the beginning of the year. Since then, CRTX shares have decreased by 24.4% and is now trading at GBX 9. View the best growth stocks for 2024 here. How do I buy shares of CRISM Therapeutics? Shares of CRTX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. Industry, Sector and Symbol Stock ExchangeLON SectorBasic Materials Industry Other Industrial Metals & Mining Sub-IndustryN/A Current SymbolLON:CRTX CUSIPN/A CIKN/A Webwww.crismtherapeutics.com PhoneN/AFaxN/AEmployees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX 8.22 Trailing P/E Ratio1.09 Forward P/E RatioN/A P/E GrowthN/ANet Income£-1,770,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-62.67% Return on Assets-26.77% Debt Debt-to-Equity RatioN/A Current Ratio6.56 Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueGBX 6 per share Price / Book1.50Miscellaneous Outstanding Shares32,680,000Free FloatN/AMarket Cap£2.94 million OptionableN/A Beta0.81 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (LON:CRTX) was last updated on 11/22/2024 by MarketBeat.com Staff From Our Partners[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | SponsoredBuffett Dumps $982 Million in BofA Stock—What Does He Know?Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track reco...Genesis Gold Group | SponsoredCentral Bank Abandons USDYou know what doesn't care about elections? Gold. If you want to protect your savings & retirement from our...Desko Digital | SponsoredAmerica’s Pro-Crypto AgendaCash In On the Pro-Crypto America 27 experts reveal their top picks for 2025 Crypto 101 Media | SponsoredA “Thank You Gift” From Pres. Trump - GeniusThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. ...Colonial Metals | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CRISM Therapeutics Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share CRISM Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.